Sumitomo Mitsui Trust Group Inc. Lowers Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Group Inc. lowered its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 6.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,926,084 shares of the biotechnology company’s stock after selling 138,966 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 7.10% of Arcturus Therapeutics worth $20,397,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in Arcturus Therapeutics by 5.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 207,802 shares of the biotechnology company’s stock worth $3,526,000 after acquiring an additional 10,180 shares in the last quarter. Tocqueville Asset Management L.P. grew its position in Arcturus Therapeutics by 42.7% in the fourth quarter. Tocqueville Asset Management L.P. now owns 22,400 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 6,700 shares in the last quarter. American Century Companies Inc. grew its position in Arcturus Therapeutics by 10.7% in the fourth quarter. American Century Companies Inc. now owns 47,018 shares of the biotechnology company’s stock worth $798,000 after acquiring an additional 4,547 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Arcturus Therapeutics in the fourth quarter worth $71,000. Finally, Vanguard Group Inc. grew its position in Arcturus Therapeutics by 6.8% in the fourth quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company’s stock worth $28,587,000 after acquiring an additional 107,635 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $13.64 on Friday. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.06. The company has a 50-day simple moving average of $12.45 and a two-hundred day simple moving average of $13.99. The firm has a market cap of $369.78 million, a price-to-earnings ratio of -5.39 and a beta of 2.27. Arcturus Therapeutics Holdings Inc. has a 12-month low of $8.04 and a 12-month high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.58) by $1.06. The company had revenue of $29.38 million during the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. On average, equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Wall Street Analyst Weigh In

ARCT has been the subject of several research reports. Canaccord Genuity Group cut their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 10th. Citigroup restated a “buy” rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, Scotiabank restated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of “Buy” and an average price target of $54.00.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.